NVRO

Nevro Corp. (NVRO) | Rumor.io

Nevro

NVRO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NVRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Feb 6

Globus Medical $GMED has acquired Nevro Corp. $NVRO in an all-cash transaction valued at $250 million, with a price of $5.85 per share representing a 16.53% premium over Nevro's last close.
The acquisition is expected to expand Globus Medical's treatment options for patients, and Nevro's stock price has risen 14.1% following the announcement.
The deal values Nevro Corp. at approximately $250 million, with the $5.85 per share price representing a significant premium over the company's previous market value.

Generated by AI

Sentiment

Of the messages about NVRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.25% +55.26
Bearish	—	—	—	3.75% -55.26

Bullish· Jan 27

$NVRO is making new all-time highs with high short interest, indicating a potential squeeze.
The stock has strong relative strength and a high short float of 9.51%, suggesting a potential buying opportunity.
Analysts at JMP Securities and Morgan Stanley have raised the price target to $150.00 and $142.00, respectively, with both maintaining a positive rating.

Bearish· Aug 5

The CEO's comments were seen as an embarrassment, implying that competitors' quarters were fine, unlike NVRO's, only because they stuffed the channel.
Analysts have downgraded NVRO, with multiple firms lowering their price targets, including Piper Sandler to $125, Canaccord Genuity to $112, and Wells Fargo to $122.
NVRO has withdrawn its FY21 guidance and seen a significant decline in its stock price, with some analysts moving to the sidelines after the company reported a Q2 loss and missed revenue estimates.

Generated by AI

Topics

Of the messages about NVRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Earnings· Feb 16

Nevro Corp. ($NVRO) reported Q4 2022 earnings with a GAAP EPS loss of $0.54, missing the estimate by $0.05, and revenue of $113.84M beating the estimate by $0.14M.
The company guided Q1 2023 revenue of $94-$96M, representing growth of 7-9% over prior year, and a GAAP net loss of $(38.9)-$(37.9)M.
Nevro Corp. also provided FY 2023 revenue guidance of $4450-$455M, representing growth of 10-12% over prior year, and a GAAP net loss of $(88)-$(83)M.

Analysts· Feb 24

Piper Sandler lowered its price target for Nevro Corp. ($NVRO) to $65.00 from $92.00.
SVB Leerink maintained an Outperform rating for Nevro Corp. ($NVRO) and lowered its price target to $85.00 from $105.00.
Wells Fargo maintained an Overweight rating for Nevro Corp. ($NVRO) and lowered its price target to $90.00 from $116.00.

Announcements· Mar 20

Nevro Corp. ($NVRO) has reached a management agreement with hedge fund Broadfin Capital.
Nevro has appointed a new CEO and made board appointments to help grow its spinal cord stimulation technology.
Nevro shares have surged 24.2% in premarket trading following the announcements.

Generated by AI

Community

Of the messages about NVRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	28.68%
Newcomers	100%	100%	100%	71.32%

Regulars· Aug 7

Piper Sandler, Wells Fargo, and JMP Securities have all downgraded Nevro Corp. due to revised guidance, with Wells Fargo lowering its price target to $5.50 and JP Morgan downgrading to Underweight from Neutral.
Nevro Corp.'s stock has plummeted, with a -33.83% drop in the pre-market, following the release of a new SC13G/A filing by Blackrock Inc. revealing a 10.1% ownership stake.
The company's second-quarter 2024 earnings call transcript is now available, providing insight into the financial performance of Nevro Corp.

Newcomers· Aug 5

Several firms have downgraded Nevro Corp.'s stock, including Canaccord Genuity, Wells Fargo, William Blair, and Citi, citing near-term visibility challenges and Covid uncertainties.
The company has withdrawn its FY outlook due to concerns over the ongoing pandemic, which has impacted its business.
Analysts have cut price targets for Nevro Corp.'s stock, with some citing the recent 25% drop in share price as a result of the withdrawn outlook and downgrades from these firms.

Generated by AI

Also Discussed

Investors talking about NVRO also mention

#	Name	Attention
1	Dentsply Sirona Inc.XRAY	0%new
2	EGRX - Eagle Pharmaceuticals, Inc.	——
3	ABMD - Abiomed, Inc.	——
4	Inogen Inc.INGN	0%new
5	Boston Scientific Corp.BSX	0.03%-0.02
6	Edwards Lifesciences CorporationEW	0%new
7	RDUS - Radius Recycling, Inc.	——
8	AMED - Amedisys, Inc.	——
9	Cognex CorpCGNX	0%+0
10	DexCom Inc.DXCM	0%0

Nevro Corp.

Location

Social

What share of all stock conversation is about NVRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Feb 6

Globus Medical $GMED has acquired Nevro Corp. $NVRO in an all-cash transaction valued at $250 million, with a price of $5.85 per share representing a 16.53% premium over Nevro's last close.
The acquisition is expected to expand Globus Medical's treatment options for patients, and Nevro's stock price has risen 14.1% following the announcement.
The deal values Nevro Corp. at approximately $250 million, with the $5.85 per share price representing a significant premium over the company's previous market value.

Generated by AI

Sentiment

Of the messages about NVRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.25% +55.26
Bearish	—	—	—	3.75% -55.26

Bullish· Jan 27

$NVRO is making new all-time highs with high short interest, indicating a potential squeeze.
The stock has strong relative strength and a high short float of 9.51%, suggesting a potential buying opportunity.
Analysts at JMP Securities and Morgan Stanley have raised the price target to $150.00 and $142.00, respectively, with both maintaining a positive rating.

Bearish· Aug 5

The CEO's comments were seen as an embarrassment, implying that competitors' quarters were fine, unlike NVRO's, only because they stuffed the channel.
Analysts have downgraded NVRO, with multiple firms lowering their price targets, including Piper Sandler to $125, Canaccord Genuity to $112, and Wells Fargo to $122.
NVRO has withdrawn its FY21 guidance and seen a significant decline in its stock price, with some analysts moving to the sidelines after the company reported a Q2 loss and missed revenue estimates.

Generated by AI

Topics

Of the messages about NVRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Earnings· Feb 16

Nevro Corp. ($NVRO) reported Q4 2022 earnings with a GAAP EPS loss of $0.54, missing the estimate by $0.05, and revenue of $113.84M beating the estimate by $0.14M.
The company guided Q1 2023 revenue of $94-$96M, representing growth of 7-9% over prior year, and a GAAP net loss of $(38.9)-$(37.9)M.
Nevro Corp. also provided FY 2023 revenue guidance of $4450-$455M, representing growth of 10-12% over prior year, and a GAAP net loss of $(88)-$(83)M.

Analysts· Feb 24

Piper Sandler lowered its price target for Nevro Corp. ($NVRO) to $65.00 from $92.00.
SVB Leerink maintained an Outperform rating for Nevro Corp. ($NVRO) and lowered its price target to $85.00 from $105.00.
Wells Fargo maintained an Overweight rating for Nevro Corp. ($NVRO) and lowered its price target to $90.00 from $116.00.

Announcements· Mar 20

Nevro Corp. ($NVRO) has reached a management agreement with hedge fund Broadfin Capital.
Nevro has appointed a new CEO and made board appointments to help grow its spinal cord stimulation technology.
Nevro shares have surged 24.2% in premarket trading following the announcements.

Generated by AI

Community

Of the messages about NVRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	28.68%
Newcomers	100%	100%	100%	71.32%

Regulars· Aug 7

Piper Sandler, Wells Fargo, and JMP Securities have all downgraded Nevro Corp. due to revised guidance, with Wells Fargo lowering its price target to $5.50 and JP Morgan downgrading to Underweight from Neutral.
Nevro Corp.'s stock has plummeted, with a -33.83% drop in the pre-market, following the release of a new SC13G/A filing by Blackrock Inc. revealing a 10.1% ownership stake.
The company's second-quarter 2024 earnings call transcript is now available, providing insight into the financial performance of Nevro Corp.

Newcomers· Aug 5

Several firms have downgraded Nevro Corp.'s stock, including Canaccord Genuity, Wells Fargo, William Blair, and Citi, citing near-term visibility challenges and Covid uncertainties.
The company has withdrawn its FY outlook due to concerns over the ongoing pandemic, which has impacted its business.
Analysts have cut price targets for Nevro Corp.'s stock, with some citing the recent 25% drop in share price as a result of the withdrawn outlook and downgrades from these firms.

Generated by AI

Nevro

Social

Feb 6

Sentiment

Bullish· Jan 27

Bearish· Aug 5

Topics

Earnings· Feb 16

Analysts· Feb 24

Announcements· Mar 20

Community

Regulars· Aug 7

Newcomers· Aug 5

Also Discussed

Nevro Corp.

Company Information

Location

Also Discussed

Social

Feb 6

Sentiment

Bullish· Jan 27

Bearish· Aug 5

Topics

Earnings· Feb 16

Analysts· Feb 24

Announcements· Mar 20

Community

Regulars· Aug 7

Newcomers· Aug 5